220 related articles for article (PubMed ID: 16246562)
1. Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2).
Ulmschneider S; Negri M; Voets M; Hartmann RW
Bioorg Med Chem Lett; 2006 Jan; 16(1):25-30. PubMed ID: 16246562
[TBL] [Abstract][Full Text] [Related]
2. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.
Lucas S; Heim R; Negri M; Antes I; Ries C; Schewe KE; Bisi A; Gobbi S; Hartmann RW
J Med Chem; 2008 Oct; 51(19):6138-49. PubMed ID: 18763754
[TBL] [Abstract][Full Text] [Related]
3. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
Bureik M; Hübel K; Dragan CA; Scher J; Becker H; Lenz N; Bernhardt R
Mol Cell Endocrinol; 2004 Mar; 217(1-2):249-54. PubMed ID: 15134825
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors.
LaSala D; Shibanaka Y; Jeng AY
Anal Biochem; 2009 Nov; 394(1):56-61. PubMed ID: 19622340
[TBL] [Abstract][Full Text] [Related]
5. Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.
Lucas S; Negri M; Heim R; Zimmer C; Hartmann RW
J Med Chem; 2011 Apr; 54(7):2307-19. PubMed ID: 21384875
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Voets M; Antes I; Scherer C; Müller-Vieira U; Biemel K; Marchais-Oberwinkler S; Hartmann RW
J Med Chem; 2006 Apr; 49(7):2222-31. PubMed ID: 16570918
[TBL] [Abstract][Full Text] [Related]
7. In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.
Lucas S; Heim R; Ries C; Schewe KE; Birk B; Hartmann RW
J Med Chem; 2008 Dec; 51(24):8077-87. PubMed ID: 19049427
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
Roumen L; Peeters JW; Emmen JM; Beugels IP; Custers EM; de Gooyer M; Plate R; Pieterse K; Hilbers PA; Smits JF; Vekemans JA; Leysen D; Ottenheijm HC; Janssen HM; Hermans JJ
J Med Chem; 2010 Feb; 53(4):1712-25. PubMed ID: 20121113
[TBL] [Abstract][Full Text] [Related]
9. Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.
Heim R; Lucas S; Grombein CM; Ries C; Schewe KE; Negri M; Müller-Vieira U; Birk B; Hartmann RW
J Med Chem; 2008 Aug; 51(16):5064-74. PubMed ID: 18672861
[TBL] [Abstract][Full Text] [Related]
10. The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.
Adams CM; Hu CW; Jeng AY; Karki R; Ksander G; Lasala D; Leung-Chu J; Liang G; Liu Q; Meredith E; Rao C; Rigel DF; Shi J; Smith S; Springer C; Zhang C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4324-7. PubMed ID: 20615692
[TBL] [Abstract][Full Text] [Related]
11. Indole derivatives as potent inhibitors of 5-lipoxygenase: design, synthesis, biological evaluation, and molecular modeling.
Zheng M; Zheng M; Ye D; Deng Y; Qiu S; Luo X; Chen K; Liu H; Jiang H
Bioorg Med Chem Lett; 2007 May; 17(9):2414-20. PubMed ID: 17336065
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel hydroxy-thiazoles as HIF-alpha prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation.
Tegley CM; Viswanadhan VN; Biswas K; Frohn MJ; Peterkin TA; Chang C; Bürli RW; Dao JH; Veith H; Rogers N; Yoder SC; Biddlecome G; Tagari P; Allen JR; Hungate RW
Bioorg Med Chem Lett; 2008 Jul; 18(14):3925-8. PubMed ID: 18579373
[TBL] [Abstract][Full Text] [Related]
13. Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors.
Orvieto F; Branca D; Giomini C; Jones P; Koch U; Ontoria JM; Palumbi MC; Rowley M; Toniatti C; Muraglia E
Bioorg Med Chem Lett; 2009 Aug; 19(15):4196-200. PubMed ID: 19541484
[TBL] [Abstract][Full Text] [Related]
14. Structure-based virtual screening approach to identify novel classes of Cdc25B phosphatase inhibitors.
Park H; Li M; Choi J; Cho H; Ham SW
Bioorg Med Chem Lett; 2009 Aug; 19(15):4372-5. PubMed ID: 19500977
[TBL] [Abstract][Full Text] [Related]
15. Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors.
Park H; Bahn YJ; Ryu SE
Bioorg Med Chem Lett; 2009 Aug; 19(15):4330-4. PubMed ID: 19497739
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone synthase inhibitors: pharmacological and clinical aspects.
Jansen PM; van den Meiracker AH; Jan Danser AH
Curr Opin Investig Drugs; 2009 Apr; 10(4):319-26. PubMed ID: 19337952
[TBL] [Abstract][Full Text] [Related]
17. Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.
Waelchli R; Bollbuck B; Bruns C; Buhl T; Eder J; Feifel R; Hersperger R; Janser P; Revesz L; Zerwes HG; Schlapbach A
Bioorg Med Chem Lett; 2006 Jan; 16(1):108-12. PubMed ID: 16236504
[TBL] [Abstract][Full Text] [Related]
18. Exploring QSAR for CYP11B2 binding affinity and CYP11B2/CYP11B1 selectivity of diverse functional compounds using GFA and G/PLS techniques.
Roy PP; Roy K
J Enzyme Inhib Med Chem; 2010 Jun; 25(3):354-69. PubMed ID: 20030574
[TBL] [Abstract][Full Text] [Related]
19. Novel 2D fingerprints for ligand-based virtual screening.
Ewing T; Baber JC; Feher M
J Chem Inf Model; 2006; 46(6):2423-31. PubMed ID: 17125184
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel series of Notch-sparing gamma-secretase inhibitors.
Kreft A; Harrison B; Aschmies S; Atchison K; Casebier D; Cole DC; Diamantidis G; Ellingboe J; Hauze D; Hu Y; Huryn D; Jin M; Kubrak D; Lu P; Lundquist J; Mann C; Martone R; Moore W; Oganesian A; Porte A; Riddell DR; Sonnenberg-Reines J; Stock JR; Sun SC; Wagner E; Woller K; Xu Z; Zhou H; Steven Jacobsen J
Bioorg Med Chem Lett; 2008 Jul; 18(14):4232-6. PubMed ID: 18556202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
